Cancer Treatment-Related Cardiotoxicity Publications

This list provides links to scientific publications that may be of interest to researchers studying cardiotoxicities related to cancer treatments, but it is not exhaustive. If you have suggestions for additional publications to add, please contact Nonniekaye Shelburne, C.R.N.P., M.S., A.O.C.N., Program Director in EGRP's Clinical and Translational Epidemiology Branch.

You may click on the table headers below to sort alphabetically by the first author, publication year, scientific area, cancer treatment, subject population, toxicity, or study type.

Filter Table

Pub. Year:

Scientific Area:

Cancer Treatment:

Subject Pop.:

Toxicity:

Study Type:

Article Pub. Year Scientific Area Cancer Treatment Subject Pop. Toxicity * Study Type
Fedele C, Riccio G, Coppola C, et al: Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitorsExternal Web Site Policy. Breast Cancer Res Treat. 133:511-21, 2012 2012 Detection Targeted Therapy Pre-clinical LVEF / Heart Failure Biological Study
Lenihan D, Suter T, Brammer M, et al: Pooled analysis of cardiac safety in patients with cancer treated with pertuzumabExternal Web Site Policy. Ann Oncol. 23:791-800, 2012 2012 Epidemiology / Risk Targeted Therapy Adult LVEF / Heart Failure Observational Epidemiological Study - Retrospective
McMurray JJ, Adamopoulos S, Anker SD, et al: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCExternal Web Site Policy. Eur Heart J. 2012 2012 General Multi-modality Adult LVEF / Heart Failure Guidelines
Serrano C, Cortes J, De Mattos-Arruda L, et al: Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factorsExternal Web Site Policy. Ann Oncol. 23:897-902, 2012 2012 Epidemiology / Risk Targeted Therapy Older Adult LVEF / Heart Failure Observational Epidemiological Study - Retrospective
Steingart RM, Bakris GL, Chen HX, et al: Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitorsExternal Web Site Policy. Am Heart J. 163:156-63, 2012 2012 General Targeted Therapy Adult Hypertension Consensus
Tarantini L, Cioffi G, Gori S, et al: Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancerExternal Web Site Policy. J Card Fail. 18:113-9, 2012 2012 Epidemiology / Risk Targeted Therapy Adult LVEF / Heart Failure Observational Epidemiological Study - Prospective
Tarantini L, Gori S, Faggiano P, et al: Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysisExternal Web Site Policy. Ann Oncol. 2012 2012 Epidemiology / Risk Targeted Therapy Older Adult LVEF / Heart Failure & Hyptertension Observational Epidemiological Study - Retrospective
Visscher H, Ross CJ, Rassekh SR, et al: Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in childrenExternal Web Site Policy. J Clin Oncol. 30:1422-8, 2012 2012 Epidemiology / Risk Chemotherapy Pediatric LVEF / Heart Failure Observational Epidemiological Study - Retrospective
Aapro M, Bernard-Marty C, Brain EG, et al: Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paperExternal Web Site Policy. Ann Oncol. 22:257-67, 2011 2011 General Chemotherapy Older Adult LVEF / Heart Failure Consensus
Appel JM, Sogaard P, Mortensen CE, et al: Tissue-Doppler assessment of cardiac left ventricular function during short-term adjuvant epirubicin therapy for breast cancerExternal Web Site Policy. J Am Soc Echocardiogr. 24:200-6, 2011 2011 Detection Chemotherapy Adult LVEF / Heart Failure Observational Epidemiological Study - Prospective
Cendales R, Schiappacasse L, Schnitman F, et al: Helical tomotherapy in patients with breast cancer and complex treatment volumesExternal Web Site Policy. Clin Transl Oncol. 13:268-74, 2011 2011 Prevention Radiation Adult LVEF / Heart Failure Observational Epidemiological Study - Prospective
Eschenhagen T, Force T, Ewer MS, et al: Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of CardiologyExternal Web Site Policy. Eur J Heart Fail. 13:1-10, 2011 2011 General Multi-modality Pre-clinical General cardiotoxicity Consensus
Feola M, Garrone O, Occelli M, et al: Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptideExternal Web Site Policy. Int J Cardiol. 148:194-8, 2011 2011 Detection Chemotherapy Adult LVEF / Heart Failure Observational Epidemiological Study - Prospective
Haque R, Yood MU, Geiger AM, et al: Long-term safety of radiotherapy and breast cancer laterality in older survivorsExternal Web Site Policy. Cancer Epidemiol Biomarkers Prev. 20:2120-6, 2011 2011 Epidemiology / Risk Radiation Older Adult LVEF / Heart Failure Observational Epidemiological Study - Retrospective
Konishi M, Haraguchi G, Ohigashi H, et al: Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK up-regulationExternal Web Site Policy. Cardiovasc Res. 89:309-19, 2011 2011 Prevention Chemotherapy Pre-clinical LVEF / Heart Failure Biological Study
Morris PG, Chen C, Steingart R, et al: Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinibExternal Web Site Policy. Clin Cancer Res. 17:3490-9, 2011 2011 Detection Multi-modality Adult LVEF / Heart Failure Observational Epidemiological Study - Prospective
Pituskin E, Haykowsky M, Mackey JR, et al: Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRIExternal Web Site Policy. BMC Cancer. 11:318, 2011 2011 Prevention Targeted Therapy Adult LVEF / Heart Failure Randomized Clinical Trial
Sawaki M, Mukai H, Tokudome N, et al: Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort studyExternal Web Site Policy. Breast Cancer. 2011 2011 Epidemiology / Risk Targeted Therapy Older Adult LVEF / Heart Failure Observational Epidemiological Study - Retrospective
Sawaya H, Sebag IA, Plana JC, et al: Early detection and prediction of cardiotoxicity in chemotherapy-treated patientsExternal Web Site Policy. Am J Cardiol. 107:1375-80, 2011 2011 Epidemiology / Risk Chemotherapy Adult LVEF / Heart Failure Observational Epidemiological Study - Retrospective
Tikoo K, Sane MS, Gupta C: Tannic acid ameliorates doxorubicin-induced cardiotoxicity and potentiates its anti-cancer activity: potential role of tannins in cancer chemotherapyExternal Web Site Policy. Toxicol Appl Pharmacol. 251:191-200, 2011 2011 Prevention Chemotherapy Pre-clinical LVEF / Heart Failure Biological Study
van Hasselt JG, Boekhout AH, Beijnen JH, et al: Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicityExternal Web Site Policy. Clin Pharmacol Ther. 90:126-32, 2011 2011 Epidemiology / Risk Targeted Therapy Adult LVEF / Heart Failure Observational Epidemiological Study - Retrospective
Xin YF, Wan LL, Peng JL, et al: Alleviation of the acute doxorubicin-induced cardiotoxicity by Lycium barbarum polysaccharides through the suppression of oxidative stressExternal Web Site Policy. Food Chem Toxicol. 49:259-64, 2011 2011 Prevention Chemotherapy Pre-clinical LVEF / Heart Failure Biological Study
Blaes AH, Gaillard P, Peterson BA, et al: Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapyExternal Web Site Policy. Breast Cancer Res Treat. 122:585-90, 2010 2010 Prevention Chemotherapy Adult LVEF / Heart Failure Observational Epidemiological Study - Retrospective
Cardinale D, Colombo A, Lamantia G, et al: Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapyExternal Web Site Policy. J Am Coll Cardiol. 55:213-20, 2010 2010 Cardiotoxicity Management Chemotherapy Adult LVEF / Heart Failure Observational Epidemiological Study - Prospective
Cardinale D, Colombo A, Torrisi R, et al: Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluationExternal Web Site Policy. J Clin Oncol. 28:3910-6, 2010 2010 Detection Targeted Therapy Adult LVEF / Heart Failure Observational Epidemiological Study - Prospective
Georgakopoulos P, Roussou P, Matsakas E, et al: Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-upExternal Web Site Policy. Am J Hematol. 85:894-6, 2010 2010 Prevention Chemotherapy Adult LVEF / Heart Failure Randomized Clinical Trial
Lenihan DJ, Cardinale D, Cipolla CM: The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology SocietyExternal Web Site Policy. Prog Cardiovasc Dis. 53:88-93, 2010 2010 General Multi-modality General General cardiotoxicity Consensus
Lindenfeld J, Kelly PA: Developing a cardiology-oncology clinical practice guidelineExternal Web Site Policy. Prog Cardiovasc Dis. 53:173-9, 2010 2010 General Multi-modality General General cardiotoxicity Consensus
Lipshultz SE, Scully RE, Lipsitz SR, et al: Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trialExternal Web Site Policy. Lancet Oncol. 11:950-61, 2010 2010 Epidemiology / Risk Chemotherapy Pediatric LVEF / Heart Failure Randomized Clinical Trial
Maitland ML, Bakris GL, Black HR, et al: Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitorsExternal Web Site Policy. J Natl Cancer Inst. 102:596-604, 2010 2010 General Targeted Therapy Adult Hypertension Consensus
Meacham LR, Chow EJ, Ness KK, et al: Cardiovascular risk factors in adult survivors of pediatric cancer--a report from the childhood cancer survivor studyExternal Web Site Policy. Cancer Epidemiol Biomarkers Prev. 19:170-81, 2010 2010 Epidemiology / Risk Multi-modality Pediatric Cancer Survivors General cardiotoxicity Observational Epidemiological Study - Retrospective
van Dalen EC, Michiels EM, Caron HN, et al: Different anthracycline derivates for reducing cardiotoxicity in cancer patientsExternal Web Site Policy. Cochrane Database Syst. Rev:CD005006, 2010 2010 Epidemiology / Risk Chemotherapy Adult LVEF / Heart Failure Meta Analysis / Systematic Review
Van der Pal HJ, van Dalen EC, Hauptmann M, et al: Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up studyExternal Web Site Policy. Arch Intern Med. 170:1247-55, 2010 2010 Epidemiology / Risk Multi-modality Pediatric Cancer Survivors LVEF / Heart Failure Observational Epidemiological Study - Retrospective
Yoon GJ, Telli ML, Kao DP, et al: Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?External Web Site Policy J Am Coll Cardiol. 56:1644-50, 2010 2010 Cardiotoxicity Management Multi-modality Adult LVEF / Heart Failure Observational Epidemiological Study - Retrospective
Bi X, Deng Y, Zeng F, et al: Evaluation of epirubicin-induced cardiotoxicity by two-dimensional strain echocardiography in breast cancer patientsExternal Web Site Policy. J Huazhong Univ Sci Technolog Med Sci. 29:391-4, 2009 2009 Detection Chemotherapy Adult LVEF / Heart Failure Randomized Clinical Trial
Du XL, Xia R, Liu CC, et al: Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancerExternal Web Site Policy. Cancer. 115:5296-308, 2009 2009 Epidemiology / Risk Chemotherapy Older Adult LVEF / Heart Failure Observational Epidemiological Study - Retrospective
Guglin M, Hartlage G, Reynolds C, et al: Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective studyExternal Web Site Policy. J Card Fail. 15:651-7, 2009 2009 Epidemiology / Risk Targeted Therapy Adult LVEF / Heart Failure Observational Epidemiological Study - Retrospective
Hare JL, Brown JK, Leano R, et al: Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumabExternal Web Site Policy. Am Heart J. 158:294-301, 2009 2009 Detection Targeted Therapy Adult LVEF / Heart Failure Observational Epidemiological Study - Prospective
Hunt SA, Abraham WT, Chin MH, et al: 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung TransplantationExternal Web Site Policy. Circulation. 119:e391-479, 2009 2009 Cardiotoxicity Management Multi-modality General LVEF / Heart Failure Guidelines
Jones AL, Barlow M, Barrett-Lee PJ, et al: Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoringExternal Web Site Policy. Br J Cancer. 100:684-92, 2009 2009 Cardiotoxicity Management Targeted Therapy Adult LVEF / Heart Failure Consensus
Morris PG, Dickler M, McArthur HL, et al: Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fractionExternal Web Site Policy. J Clin Oncol. 27:6117-23, 2009 2009 Epidemiology / Risk Chemotherapy Adult LVEF / Heart Failure Randomized Clinical Trial
Mulrooney DA, Yeazel MW, Kawashima T, et al: Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohortExternal Web Site Policy. BMJ. 339:b4606, 2009 2009 Epidemiology / Risk Multi-modality Pediatric Cancer Survivors LVEF / Heart Failure Observational Epidemiological Study - Retrospective
Dranitsaris G, Rayson D, Vincent M, et al: The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclinesExternal Web Site Policy. Breast Cancer Res Treat. 107:443-50, 2008 2008 Epidemiology / Risk Chemotherapy Adult LVEF / Heart Failure Randomized Clinical Trial
Mackey JR, Clemons M, Cote MA, et al: Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working GroupExternal Web Site Policy. Curr Oncol. 15:24-35, 2008 2008 Cardiotoxicity Management Targeted Therapy Adult LVEF / Heart Failure Consensus
Perez EA, Koehler M, Byrne J, et al: Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trialsExternal Web Site Policy. Mayo Clin Proc. 83:679-86, 2008 2008 Epidemiology / Risk Targeted Therapy Adult LVEF / Heart Failure Randomized Clinical Trial
Ryberg M, Nielsen D, Cortese G, et al: New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patientsExternal Web Site Policy. J Natl Cancer Inst. 100:1058-67, 2008 2008 Epidemiology / Risk Chemotherapy Adult LVEF / Heart Failure Observational Epidemiological Study - Retrospective
Telli ML, Witteles RM, Fisher GA, et al: Cardiotoxicity associated with the cancer therapeutic agent sunitinib malateExternal Web Site Policy. Ann Oncol. 19:1613-8, 2008 2008 Epidemiology / Risk Targeted Therapy Adult LVEF / Heart Failure Observational Epidemiological Study - Retrospective
Carver JR, Shapiro CL, Ng A, et al: American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effectsExternal Web Site Policy. J Clin Oncol. 25:3991-4008, 2007 2007 Epidemiology / Risk Multi-modality Adult LVEF / Heart Failure Meta Analysis / Systematic Review
Robert J: Long-term and short-term models for studying anthracycline cardiotoxicity and protectorsExternal Web Site Policy. Cardiovasc Toxicol. 7:135-9, 2007 2007 Detection Chemotherapy Pre-clinical LVEF / Heart Failure Biological Study
Suter TM, Procter, M, van Veldhuisen, DJ, et al: Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trialExternal Web Site Policy. J of Cl Oncol. 25:3859-65, 2007 2007 Epidemiology / Risk Targeted Therapy Adult LVEF / Heart Failure Randomized Clinical Trial
Cardinale D, Colombo A, Sandri MT, et al: Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibitionExternal Web Site Policy. Circulation. 114:2474-81, 2006 2006 Prevention Chemotherapy Adult LVEF / Heart Failure Randomized Clinical Trial
Guarneri V, Lenihan DJ, Valero V, et al: Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experienceExternal Web Site Policy. J Clin Oncol. 24:4107-15, 2006 2006 Epidemiology / Risk Targeted Therapy Adult LVEF / Heart Failure Observational Epidemiological Study - Retrospective
Focan C, Graas MP, Beauduin M, et al: Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trialExternal Web Site Policy. Anticancer Res. 25:1211-7, 2005 2005 Prevention Chemotherapy Adult LVEF / Heart Failure Randomized Clinical Trial
Swain SM, Vici P: The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel reviewExternal Web Site Policy. J Cancer Res Clin Oncol. 130:1-7, 2004 2004 Prevention Chemotherapy General LVEF / Heart Failure Consensus
Schultz PN, Beck ML, Stava C, et al: Health profiles in 5836 long-term cancer survivorsExternal Web Site Policy. Int J Cancer. 104:488-95, 2003 2003 Epidemiology / Risk Multi-modality Adult General cardiotoxicity Observational Epidemiological Study - Prospective
Kremer LCM, van der Pal HJH, Offringa M, et al: Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic reviewExternal Web Site Policy. Annals of Oncology. 13:819-829, 2002 2002 Epidemiology / Risk Chemotherapy Adult LVEF / Heart Failure Meta Analysis / Systematic Review
Mertens AC, Yasui Y, Neglia JP, et al: Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor StudyExternal Web Site Policy. J Clin Oncol. 19:3163-72, 2001 2001 Epidemiology / Risk Multi-modality Pediatric Cancer Survivors General cardiotoxicity Observational Epidemiological Study - Retrospective

*LVEF = left ventricular ejection fraction

Return to Top